|Application ||WB, IHC-P, E|
|Calculated MW||33520 Da|
|Antigen Region||1-30 aa|
|Other Names||Homeobox protein CDX-2, CDX-3, Caudal-type homeobox protein 2, CDX2, CDX3|
|Target/Specificity||This CDX2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human CDX2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CDX2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Involved in the transcriptional regulation of multiple genes expressed in the intestinal epithelium. Important in broad range of functions from early differentiation to maintenance of the intestinal epithelial lining of both the small and large intestine.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The caudal type homeo box transcription factors 1 (CDX1) and 2 (CDX2) are candidates for directing intestinal development, differentiation, and maintenance of the intestinal phenotype. CDX1 and CDX2 expression is widely present in the human intestinal and colonic mucosae, but not in the gastric mucosa, suggesting a possible role in the terminal differentiation of the intestine. Increased CDX2 expression is associated with chronic atrophic gastritis. Detectable expression of CDX2 precedes expression of CDX1 during the progression of intestinal metaplasia, thus expression of CDX2 may trigger the initiation and development of intestinal metaplasia. Markedly reduced or absent CDX2 expression was noted by immunohistochemistry in 13 of 15 (87%) large cell minimally differentiated carcinomas (LCMDCs), whereas only 1 of the 25 (4%) differentiated adenocarcinomas (DACs) showed reduced CDX2 expression. Thus, a significant decrease in human CDX1 and/or CDX2 expression may be associated with colorectal tumorigenesis.
Phillips, R.W., et al., Am. J. Surg. Pathol. 27(11):1442-1447 (2003).
Bai, Y.Q., et al., Oncogene 22(39):7942-7949 (2003).
Yamamoto, H., et al., Biochem. Biophys. Res. Commun. 300(4):813-818 (2003).
Eda, A., et al., J. Gastroenterol. 37(2):94-100 (2002).
Moucadel, V., et al., Biochem. Biophys. Res. Commun. 297(3):607-615 (2002).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.